Thermo Fisher Scientific Inc. (TMO) Q3 2026 (USD): Adj. EPS 6.68 (exp. 6.40), Revenue 12.1bln (exp. 11.95bln), Adj. EBIT 2.97bln (exp. 2.86bln)

Thermo Fisher Scientific Inc. (TMO) Q3 2026 (USD): Adj. EPS 6.68 (exp. 6.40), Revenue 12.1bln (exp. 11.95bln), Adj. EBIT 2.97bln (exp. 2.86bln)

A clean beat on all three headline lines, with adjusted EPS, revenue and EBIT each ahead of consensus by a modest margin. For large-cap life sciences tools names, beats of this size have historically been a necessary but not sufficient condition for a positive reaction; the group trades on guidance and organic growth trajectory rather than the quarter itself, and episodes where the print beats but organic growth or the full-year outlook disappoints have tended to fade or reverse the initial move. The distinctions that matter here are organic versus inorganic growth, since this name leans heavily on M&A, and the split between instrument demand tied to biopharma funding conditions and recurring consumables revenue, which carries the multiple. Peer read-throughs to the rest of the tools and diagnostics complex have typically followed within the session. The follow-ons are the call commentary on bioproduction demand, academic and government funding trends, China, and any change to full-year organic growth and margin guidance, which is where the stock has historically been made or unbroken on results days.